Desensitization therapy for preexisted anti-HLA antibody with anti-CD20 Antibody, plasma exchange, and immunoglobulin in kidney transplantatio
- Conditions
- kidney transplantation recipients with preexisted anti-HLA antibody
- Registration Number
- JPRN-UMIN000020829
- Lead Sponsor
- Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 6
Not provided
1) The patients with serious hypersensitivity or medical history of anaphylaxis for the products derived from mouse protein, Rituximab, immunoglobulin, and an integrent of the albumin to prepare plasma exchange. 2) The patients whom the medical attendant judged when the exacerbation of the sign exceeded benefit of Rituximab among them who have severe infectious diseases, a cardiac dysfunction, respiratory diseases, or a bone marrow dysfunction. 3) The patients with an medical history of the drug hypersensitivity and the allergic to albumin (preparation for plasma exchange), Rituximab or immunoglobulin whom the medical attendant judged when these adverse effects exceeded the benefits of these medications.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method